#United States #Hamilton #radiopharmaceuticals #AtomVie #Jubilant

AtomVie and Jubilant Radiopharma: A Powerful Partnership

In a significant move within the radiopharmaceutical industry, AtomVie Global Radiopharma has announced a strategic alliance with Jubilant DraxImage Inc., known as Jubilant Radiopharma. This partnership aims to fortify the logistics and distribution framework supporting AtomVie's expanding portfolio of radiopharmaceutical programs, particularly during clinical trials. The collaboration formalized through a Logistics and Regulatory Services Agreement, is designed to enhance operational efficiencies while upholding the highest standards of safety and regulatory compliance.

Bruno Paquin, the CEO of AtomVie, emphasized the partnership’s importance in the growing landscape of radiopharmaceuticals. "As the sector expands, robust logistics and distribution capabilities become paramount in ensuring the timely and reliable delivery of products to both patients and clinical trial sites," he stated. With Jubilant's rich experience in pharmacy networks and regulatory expertise, AtomVie is poised to enhance its offerings in the clinical development domain.

Strengthening Distribution Channels

Under the terms of this strategic alliance, Jubilant Radiopharma will assume responsibility for the receipt, handling, and distribution of AtomVie-manufactured radiopharmaceuticals across its extensive pharmacy network in the United States. This initiative is not merely a transaction; it symbolizes a shared commitment between both companies to streamline the delivery process, ensuring that clinical sites can access the products they need efficiently and reliably.

Harsher Singh, the CEO of Jubilant Radiopharma, commented on the ambition underlying this collaboration. He stated, "Our mission is to advance the secure and compliant delivery of radiopharmaceutical therapies across North America. Our expansive distribution network and regulatory know-how make us a valuable ally in this journey. The partnership with AtomVie reflects our mutual dedication to enhancing innovation and patient access to cutting-edge radiopharmaceutical treatments."

Enhanced Service Offerings

This partnership is set to elevate AtomVie's service suite significantly. By leveraging Jubilant’s established infrastructure and expertise that spans clinical trials, therapeutic dispensing, and commercialization, AtomVie will benefit from improved access to clinical trial locations and increased operational flexibility as it gears up for future development initiatives.

Moreover, AtomVie itself is dedicated to the clinical and commercial advancement of radiopharmaceuticals, offering integrated solutions that encompass everything from process development to GMP manufacturing, quality assurance, and regulatory guidance. Located within a state-of-the-art facility in Hamilton, Ontario, AtomVie is ideally positioned to support the global therapeutic and diagnostic needs of the pharmaceutical and biotechnology sectors.

About the Companies

AtomVie Global Radiopharma is a leading contract development and manufacturing organization (CDMO) focusing specifically on radiopharmaceuticals. With an international footprint, AtomVie provides comprehensive services critical to the progression of innovative radiotherapeutics and diagnostics across various stages of clinical and commercial operations.

On the other hand, Jubilant Radiopharma, a segment of Jubilant Pharmova Limited, is renowned for its extensive radiopharmacy network in the United States. With over 70 years of cumulative experience, Jubilant supports not only innovative diagnostic solutions but also therapeutic radiopharmaceutical programs with top-notch logistics, regulatory support, and therapeutic dispensing services.

Conclusion

Overall, the alliance between AtomVie and Jubilant Radiopharma is a promising step forward in the radiopharmaceutical landscape. By combining capabilities, the two organizations aim to address the critical logistical challenges associated with delivering radiopharmaceuticals, paving the way for improved patient access and outcomes. As they continue this journey, the partnership represents a shining example of collaboration aimed at transforming lives through the enhanced delivery of radiopharmaceutical therapies.